Coenzyme Q10
Also sold as: CoQ10 · Ubiquinone · Ubiquinol
A mitochondrial electron carrier studied as an adjunct in heart failure, migraine prevention and selected fatigue syndromes. Higher blood levels do not automatically mean more energy or better athletic performance.
Energy Longevity
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Energy: Small studies in fibromyalgia and chronic-fatigue populations suggest less fatigue; no reliable acute energy boost in healthy adults is established.
- Longevity: Heart-failure adjunct trials include survival signals with low certainty; this does not establish longer life in healthy people.
REALITY CHECK // CoQ10 is not a stimulant, and statin-related depletion does not prove everyone on a statin needs it. Some heart-failure and migraine data are favorable; statin-myalgia reviews disagree. Ubiquinol marketing overstates clinical superiority because most comparisons concern blood levels rather than patient outcomes.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // No formal EFSA or NIH UL is established in the dossier. A cited observed safe level around 1,200 mg/day is not a regulatory UL or a recommended dose; high-dose specialist studies do not establish unrestricted safety.
Summary
The clearest clinical role is adjunctive use in heart failure, with a low-certainty survival signal and somewhat more consistent cardiac-function outcomes. Migraine-frequency evidence is promising but small. Statin myalgia and blood-pressure meta-analyses conflict.
Mechanism
CoQ10 transfers electrons in mitochondrial oxidative phosphorylation and participates in redox cycling. Statins lower plasma CoQ10 through the mevalonate pathway; that mechanism does not demonstrate symptom relief from replacement.
Typical studied dose
Typical dossier trials used 100–300 mg/day. Q-SYMBIO used ubiquinone 100 mg three times daily for two years in 420 patients with chronic heart failure. Migraine prevention was assessed over at least 4–12 weeks; semen studies commonly lasted 3–6 months. Specialist mitochondrial regimens are not self-care examples.
Upper limit
No formal EFSA or NIH UL is established in the dossier. A cited observed safe level around 1,200 mg/day is not a regulatory UL or a recommended dose; high-dose specialist studies do not establish unrestricted safety.
Popular stacks with Coenzyme Q10
Not enough stack data yet. A combination with Coenzyme Q10 appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Ubiquinone: labelled CoQ10 content Best for: Matching the form used in many clinical trials. |
Extract weight · ~100% marker | 100–300 mg | Low and variable absorption; formulation and meals matter. Usually good; mild gastrointestinal symptoms are possible. |
Studied standard [FORM // REFERENCE] Enter labelled CoQ10 milligrams, not total softgel or oil mass. The molecule is not a mineral; 100% refers only to pure labelled CoQ10. |
| Ubiquinol: labelled reduced CoQ10 content Best for: Comparing labelled reduced CoQ10 amounts. |
Extract weight · ~100% marker | 100–300 mg | Some pharmacokinetic comparisons favor ubiquinol, others are comparable; clinical superiority remains unproven. Usually good. |
Good option [FORM // CHECK_LABEL] The 100–300 mg interval is an aggregate CoQ10 trial range, not a proven ubiquinol-equivalent dose for Q-SYMBIO. Oil and excipients must not be counted as CoQ10. |
| Oil-solubilized CoQ10 formulation Best for: Checking a product that lists total formulation mass. |
Unstandardized: active content unknown | no comparable trial range | Carrier and solubilization can change plasma exposure. Usually good; depends on formulation. |
Caution [FORM // CHECK_LABEL] Unknown total formulation-to-CoQ10 fraction: no conversion until the label supplies actual CoQ10 milligrams. |
Common label traps
- TRAP_01 // Ubiquinol is always worth any premium
Blood-level differences vary with formulation and do not establish superior survival, fatigue or migraine outcomes. - TRAP_02 // Everyone taking a statin must supplement
Plasma depletion is documented, but meta-analyses disagree on whether muscle symptoms improve. - TRAP_03 // A guaranteed energy and testosterone boost
Fatigue evidence is condition-specific; semen markers are not proof of a testosterone boost or live births.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- HEART-FAILURE ADJUNCT Moderate · benefit
Q-SYMBIO enrolled 420 patients and used 300 mg/day for two years, reporting fewer major events and deaths. Reviews suggest roughly 3–4 percentage-point EF improvement, but survival certainty is low and exact event percentages require source review.
PMID 25282031 PMID 35608922 PMID 39462324 - STATIN MYALGIA: FAVORABLE REVIEW Limited · benefit
A 2018 meta-analysis of 12 RCTs, 575 participants, reported a pain-score WMD of -1.60. Scale and trial heterogeneity limit interpretation.
PMID 30371340 - STATIN MYALGIA: NULL REVIEWS Limited · no benefit
Other RCT meta-analyses did not find clear improvements in muscle symptoms or CK, so a reliable clinical benefit is unresolved.
PMID 25440725 PMID 32179207 - MIGRAINE FREQUENCY Moderate · benefit
A four-RCT synthesis with 221 adults reported about 1.87 fewer attacks/month (95% CI -2.69 to -1.05); small evidence base.
PMID 33402403 PMID 30727862 PMID 30428123 - MIGRAINE SEVERITY / DURATION Limited · no benefit
The dossier synthesis found no statistically clear severity or duration benefit: VAS WMD -2.35, p=0.105; duration -6.14 hours, p=0.086.
PMID 33402403 - BLOOD PRESSURE: CONFLICT Limited · no benefit
Cochrane pooled only two RCTs with 50 participants and found a nonsignificant SBP difference of -3.68 mmHg; other cardiometabolic reviews suggest lowering. No dependable treatment effect is established.
PMID 26935713 PMID 36130103 PMID 17287847 - SEMEN MOTILITY Limited · benefit
Motility and progressive movement may improve over 3–6 months in subfertile men; count, morphology and ejaculate volume were not clearly improved in the cited synthesis. Pregnancy and live-birth benefits remain uncertain.
PMID 32271472 PMID 23912751 - EXERCISE BIOMARKERS Limited · benefit
Some reductions in CK and oxidative-stress markers do not demonstrate a faster or stronger athlete.
PMID 38479900 PMID 40367843 - ATHLETIC PERFORMANCE Limited · no benefit
Systematic reviews do not establish a consistent aerobic-performance or sport-result benefit.
PMID 37764774 PMID 26526835 - GLYCEMIC MARKERS Limited · benefit
Some small heterogeneous improvements in fasting glucose or HbA1c are reported; exact magnitude is not established in the dossier.
PMID 41859772 PMID 41630501 - FATIGUE SYNDROMES Limited · benefit
Small interventional studies and reviews suggest less fatigue in selected clinical populations, with uncertain effect size.
PMID 30935528 PMID 38220408 - MITOCHONDRIAL DISORDERS Limited · no benefit
The broad Cochrane evidence does not establish general efficacy across mitochondrial disorders. Genetic CoQ deficiency is a distinct specialist replacement context, not a consumer diagnosis.
PMID 22513923
Reader questions
Ubiquinone or ubiquinol?
Most clinical studies used ubiquinone. Ubiquinol can raise blood levels more in some comparisons, but meal and carrier effects are large and patient-outcome superiority is unproven.
Why does it make me tired rather than energized?
Drowsiness or paradoxical fatigue occurs in user reports; incidence and cause are not established. Do not assume worsening is a necessary adaptation. Persistent symptoms need review.
Does better sperm movement mean better IVF success?
No. Semen markers are surrogate outcomes and the dossier does not establish more pregnancies or live births. Fertility concerns need specialist evaluation.
Can it worsen anxiety?
Stimulation or insomnia is reported by some users, but controlled anxiety efficacy or harm evidence is not established. New severe symptoms warrant clinical review.
Stack interactions
- Caution Warfarin / vitamin K antagonists [CAUTION // REVIEW_CONTEXT]
Possible reduction of anticoagulant effect and INR is based on precautionary case-based rationale in the dossier; independent confirmation is pending. Review starting or stopping with the prescribing clinician. - Caution Statins [CAUTION // REVIEW_CONTEXT]
Statins lower plasma CoQ10; that is a biochemical effect, not proof supplementation prevents muscle symptoms.
PMID 26192349 - Caution Diabetes and blood-pressure medicines [CAUTION // REVIEW_CONTEXT]
Possible additive lowering is theoretical; the underlying clinical outcome evidence is heterogeneous. Monitor through the treating clinician. - Caution Fat-containing meal [CAUTION // REVIEW_CONTEXT]
Absorption depends on the lipid vehicle and formulation; do not convert bioavailability claims into dose multipliers.
PMID 32380795 PMID 17482886
Red flags: interactions and who should avoid it
Interactions
Warfarin effect may be reduced with a fall in INR; this dossier has no verified interaction citation and labels it precautionary. Additive glucose- or blood-pressure-lowering effects are possible but uncertain. A fat-containing meal and formulation affect absorption; selenium combination effects do not establish CoQ10-only benefit.
Avoid or ask a doctor first if
Warfarin requires clinician review and INR monitoring. Pregnancy, lactation and pediatric use require a clinical indication. Discuss perioperative use with the surgical team. Nausea, diarrhea, headache or insomnia can occur; fatigue and drowsiness are user reports rather than quantified trial incidence.
Sources (PubMed, 27)
- The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial.
PMID 25282031 · 2014 · randomized controlled trialTwo-year adjunctive heart-failure Q-SYMBIO trial, 300 mg/day.
- Coenzyme Q10 for heart failure.
PMID 35608922 · 2021 · systematic review and meta-analysisHeart-failure review used for uncertainty around mortality outcomes.
- Efficacy and safety of coenzyme Q10 in heart failure: a meta-analysis of randomized controlled trials.
PMID 39462324 · 2024 · systematic review and meta-analysisUpdated heart-failure RCT meta-analysis.
- Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials.
PMID 30371340 · 2018 · systematic review and meta-analysisFavorable statin-myopathy synthesis, contrasted with null reviews.
- Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials.
PMID 25440725 · 2015 · systematic review and meta-analysisStatin-myopathy meta-analysis with no clear benefit.
- Effect of Coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: A systematic review and meta-analysis.
PMID 32179207 · 2020 · systematic review and meta-analysisMyalgia and adherence review with no clear symptom benefit.
- Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis.
PMID 33402403 · 2021 · systematic review and meta-analysisMigraine-prevention review; frequency distinguished from severity and duration.
- Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials.
PMID 30727862 · 2020 · systematic review and meta-analysisMigraine dose-response synthesis.
- Efficacy of CoQ10 as supplementation for migraine: A meta-analysis.
PMID 30428123 · 2019 · systematic review and meta-analysisAdditional migraine RCT synthesis.
- Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension.
PMID 26935713 · 2016 · systematic review and meta-analysisSmall primary-hypertension review with nonsignificant blood-pressure result.
- Dose-Response Effect of Coenzyme Q10 Supplementation on Blood Pressure among Patients with Cardiometabolic Disorders: A Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PMID 36130103 · 2022 · systematic review and meta-analysisGRADE dose-response analysis suggesting reductions in cardiometabolic populations.
- Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials.
PMID 17287847 · 2007 · systematic review and meta-analysisEarlier hypertension synthesis underlying conflicting conclusions.
- Coenzyme Q10 effect on semen parameters: Profound or meagre?
PMID 32271472 · 2020 · systematic review and meta-analysisSemen-motility improvements with limited evidence for other parameters.
- Coenzyme Q10 and male infertility: a meta-analysis.
PMID 23912751 · 2013 · systematic review and meta-analysisMale-infertility review; clinical fertility outcomes remain uncertain.
- The effects of coenzyme Q10 supplementation on biomarkers of exercise-induced muscle damage, physical performance, and oxidative stress: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.
PMID 38479900 · 2024 · systematic review and meta-analysisExercise-damage and performance synthesis; biomarker outcomes distinguished.
- Can coenzyme Q10 supplementation reduce exercise-induced muscle damage and oxidative stress in athletes? A systematic review and meta-analysis.
PMID 40367843 · 2025 · systematic review and meta-analysisExercise-damage and oxidative-stress review.
- Coenzyme Q10 Supplementation in Athletes: A Systematic Review.
PMID 37764774 · 2023 · systematic review and meta-analysisAthlete review with uncertain ergogenic effect.
- Coenzyme Q10 Supplementation and Exercise in Healthy Humans: A Systematic Review.
PMID 26526835 · 2016 · systematic review and meta-analysisExercise review in healthy humans.
- Effects of Coenzyme Q10 Supplementation on Glycemic Control Biomarkers: An Umbrella Review of Meta-Analyses of Randomised Controlled Trials.
PMID 41859772 · 2026 · systematic review and meta-analysisGlycemic-biomarker umbrella review.
- The effects of coenzyme Q10 supplementation on glycemic control in diabetic and non-diabetic individuals: a systematic review and meta-analysis.
PMID 41630501 · 2026 · systematic review and meta-analysisHeterogeneous glycemic-control review.
- Effect of coenzyme Q10 supplementation on fatigue: A systematic review of interventional studies.
PMID 30935528 · 2019 · systematic review and meta-analysisSystematic review of fatigue interventions.
- Coenzyme Q10 supplementation in rheumatic diseases: A systematic review.
PMID 38220408 · 2024 · systematic review and meta-analysisRheumatic-disease review informing limited fatigue evidence.
- Treatment for mitochondrial disorders.
PMID 22513923 · 2012 · systematic review and meta-analysisReview of mitochondrial-disorder treatment with uncertain broad efficacy.
- Bioavailability of Coenzyme Q10: An Overview of the Absorption Process and Subsequent Metabolism.
PMID 32380795 · 2020 · narrative reviewAbsorption and metabolism review, not proof of clinical superiority.
- Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations.
PMID 17482886 · 2007 · clinical or mechanistic studyPlasma-response comparison of formulations.
- The Plasma Bioavailability of Coenzyme Q10 Absorbed from the Gut and the Oral Mucosa.
PMID 30558322 · 2018 · randomized controlled trialOral and gut bioavailability study.
- Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials.
PMID 26192349 · 2015 · systematic review and meta-analysisMeta-analysis documenting reduced plasma CoQ10 with statins.
Community comments
No approved comments yet. Comments are held for moderation.